# Legend Biotech Corp (LEGN)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/legend-biotech-corp/ JSON: https://steadybase.io/company/legend-biotech-corp.json Checked Nov 21, 2026. Latest filing read: Oct 7, 2026.

## Company

- Legal name: Legend Biotech Corp
- Ticker: LEGN (Nasdaq)
- SEC CIK: 0001801198
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Somerset, NJ
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: legendbiotech.com
- LinkedIn: https://www.linkedin.com/company/legendbiotechco.
- Next earnings date: Feb 10, 2027

## Key facts

- Revenue: $627.2M for the fiscal year ended Dec 31, 2024 (20-F filed Mar 11, 2025). Source: https://www.sec.gov/Archives/edgar/data/1801198/000180119825000012/0001801198-25-000012-index.html
- Operating income: -$136.5M for the fiscal year ended Dec 31, 2025 (20-F filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/0001801198-26-000008-index.html
- Net income: -$296.8M for the fiscal year ended Dec 31, 2025 (20-F filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/0001801198-26-000008-index.html
- Employees: 2,900 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm
- Shares outstanding: 369,886,369 as of Dec 31, 2025 (20-F filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/0001801198-26-000008-index.html
- Auditor: Ernst & Young LLP, Iselin, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm

## Business

We are a global biopharmaceutical company engaged in the discovery, development, manufacturing and commercialization of novel cell therapies for oncology and other indications. Our team of approximately 2,900 employees in the United States, China and Europe, our differentiated technology, global development and manufacturing strategy and expertise provide us with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income |
|---|---|---|---|
| Dec 31, 2024 | $627.2M | -$309.5M | -$177.0M |
| Dec 31, 2023 | $285.1M | -$528.1M | -$518.3M |
| Dec 31, 2022 | $117.0M | n/a | -$446.3M |
| Dec 31, 2021 | $68.8M | n/a | -$403.6M |
| Dec 31, 2020 | $75.0M | n/a | n/a |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/legend-biotech-corp.json

## Officers and directors

- Ingrid Zhang, Chief Executive Officer. Source: Form 4 filed Sep 16, 2026, https://www.sec.gov/Archives/edgar/data/1801198/000196434226000004/0001964342-26-000004-index.htm
- Alan Bash, Interim CEO. LinkedIn: https://linkedin.com/in/alan-bash. Source: Form 4 filed Aug 18, 2026, https://www.sec.gov/Archives/edgar/data/1801198/000190842126000005/0001908421-26-000005-index.htm
- Ying Huang, Chief Executive Officer. Source: Form 4 filed Jul 2, 2026, https://www.sec.gov/Archives/edgar/data/1801198/000196736026000008/0001967360-26-000008-index.htm
- Carlos E. Santos, Chief Financial Officer. LinkedIn: https://linkedin.com/in/carlos-santosg. Source: Form 4 filed Sep 23, 2026, https://www.sec.gov/Archives/edgar/data/1801198/000209706526000005/0002097065-26-000005-index.htm

## Insider trades (Form 4)

- Nov 17, 2026: Ingrid Zhang (Chief Executive Officer) bought 20,000 shares, about $163,200. Source: https://www.sec.gov/Archives/edgar/data/1801198/000196434226000006/0001964342-26-000006-index.htm
- Nov 13, 2026: Peter Salovey (Director) bought 20,000 shares, about $183,250. Source: https://www.sec.gov/Archives/edgar/data/1801198/000208846826000008/0002088468-26-000008-index.htm
- Sep 29, 2026: Corazon (Corsee) D. Sanders (Director) sold 27,370 shares, about $258,920. Source: https://www.sec.gov/Archives/edgar/data/1801198/000179653626000010/0001796536-26-000010-index.htm
- Sep 21, 2026: Carlos E. Santos (Chief Financial Officer) sold 5,430 shares, about $49,630. Source: https://www.sec.gov/Archives/edgar/data/1801198/000209706526000005/0002097065-26-000005-index.htm
- Jun 30, 2026: Patrick John Casey (Director) sold 6,000 shares, about $88,800. Source: https://www.sec.gov/Archives/edgar/data/1801198/000206836526000005/0002068365-26-000005-index.htm
- Jun 25, 2026: Ying Huang (Chief Executive Officer) sold 5,566 shares, about $82,265. Source: https://www.sec.gov/Archives/edgar/data/1801198/000196736026000006/0001967360-26-000006-index.htm
- Mar 25, 2026: Ying Huang (Chief Executive Officer) sold 9,936 shares, about $87,139. Source: https://www.sec.gov/Archives/edgar/data/1801198/000196736026000004/0001967360-26-000004-index.htm

## Latest filings

- 20f filed Mar 10, 2026: https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

